Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma

Nature Genetics

Volumn 47, Issue 9, 2015, Pages 987-995

  Law, Matthew H ^a   Bishop, D Timothy ^b   Lee, Jeffrey E ^c   Brossard, Myriam ^d,e   Martin, Nicholas G ^a   Moses, Eric K ^f   Song, Fengju ^g   Barrett, Jennifer H ^b   Kumar, Rajiv ^h   Easton, Douglas F ⁱ   Pharoah, Paul D P ⁱ   Swerdlow, Anthony J ^j   Kypreou, Katerina P ^k   Taylor, John C ^b   Harland, Mark ^b   Randerson Moor, Juliette ^b   Akslen, Lars A ^l,m   Andresen, Per A ⁿ   Avril, Marie Françoise ^o   Azizi, Esther ^p,q   Scarrà, Giovanna Bianchi ^r,s   Brown, Kevin M ^t   Dębniak, Tadeusz ^u   Duffy, David L ^a   Elder, David E ^v   Fang, Shenying ^c   Friedman, Eitan ^q   Galan, Pilar ^w   Ghiorzo, Paola ^r,s   Gillanders, Elizabeth M ^x   Goldstein, Alisa M ^t   Gruis, Nelleke A ^y   Hansson, Johan ^z   Helsing, Per ⁿ   Hočevar, Marko ^aa   Höiom, Veronica ^z   Ingvar, Christian ^ab   Kanetsky, Peter A ^ac   Chen, Wei V ^c   Landi, Maria Teresa ^t   Lang, Julie ^ad   Lathrop, G Mark ^ae   Lubiński, Jan ^u   MacKie, Rona M ^ad   Mann, Graham J ^af   Molven, Anders ^l,m   Montgomery, Grant W ^a   Novaković, Srdjan ^aa   Olsson, Håkan ^ab   Puig, Susana ^ag,ah   Puig Butille, Joan Anton ^ag,ah   Qureshi, Abrar A ^ai   Radford Smith, Graham L ^a,aj,ak   Van Der Stoep, Nienke ^y   Van Doorn, Remco ^y   Whiteman, David C ^a   Craig, Jamie E ^al   Schadendorf, Dirk ^am,an   Simms, Lisa A ^a   Burdon, Kathryn P ^ao   Nyholt, Dale R ^a,ap   Pooley, Karen A ⁱ   Orr, Nick ^j   Stratigos, Alexander J ^k   Cust, Anne E ^aq   Ward, Sarah V ^f   Hayward, Nicholas K ^a   Han, Jiali ^ar,as   Schulze, Hans Joachim ^at   Dunning, Alison M ⁱ   Bishop, Julia A Newton ^b   Demenais, Florence ^d,e   Amos, Christopher I ^au   MacGregor, Stuart ^a   Iles, Mark M ^b   more..

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DIDEROT   (France)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g TIANJIN MEDICAL UNIVERSITY   (China)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^k UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^l UNIVERSITY OF BERGEN   (Norway)

^m HAUKELAND UNIVERSITY HOSPITAL   (Norway)

ⁿ OSLO UNIVERSITY HOSPITAL   (Norway)

^o université Paris Cité   (France)

^p SHEBA MEDICAL CENTER   (Israel)

^q TEL AVIV UNIVERSITY   (Israel)

^r UNIVERSITY OF GENOA   (Italy)

^s UNIVERSITY OF GENOA   (Italy)

^t NATIONAL CANCER INSTITUTE   (United States)

^u POMERANIAN MEDICAL UNIVERSITY   (Poland)

^v UNIVERSITY OF PENNSYLVANIA   (United States)

^w Institut National de la Recherche Agronomique   (France)

^x NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^y LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^z KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^aa INSTITUTE OF ONCOLOGY   (Slovenia)

^ab LUND UNIVERSITY   (Sweden)

^ac H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^ad UNIVERSITY OF GLASGOW   (United Kingdom)

^ae MCGILL UNIVERSITY   (Canada)

^af UNIVERSITY OF SYDNEY   (Australia)

^ag UNIVERSITY OF BARCELONA   (Spain)

^ah CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^ai BROWN UNIVERSITY   (United States)

^aj ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^ak UNIVERSITY OF QUEENSLAND   (Australia)

^al FLINDERS UNIVERSITY   (Australia)

^am UNIVERSITY HOSPITAL ESSEN   (Germany)

^an German Consortium for Translational Cancer Research (DKTK)   (Germany)

^ao UNIVERSITY OF TASMANIA   (Australia)

^ap QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^aq UNIVERSITY OF SYDNEY   (Australia)

^ar INDIANA UNIVERSITY   (United States)

^as INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^at UNIVERSITY OF MÜNSTER   (Germany)

^au DARTMOUTH MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1B1;

ARTICLE; BIOINFORMATICS; CANCER RISK; CHROMOSOME 10Q; CHROMOSOME 11Q; CHROMOSOME 15Q; CHROMOSOME 6P; CHROMOSOME 7P; CHROMOSOME 9Q; CONTROLLED STUDY; CUTANEOUS MALIGNANT MELANOMA; CUTANEOUS MELANOMA; ENHANCER REGION; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; KERATINOCYTE; MAJOR CLINICAL STUDY; MELANOCYTE; META ANALYSIS; NEVUS; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN PIGMENTATION; TELOMERE; TRANSCRIPTION INITIATION SITE; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN CHROMOSOME; MELANOMA; SKIN TUMOR;

CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MELANOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; SKIN NEOPLASMS;

EID: 84940734774     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3373     Document Type: Article

References (92)

1. Holly, E.A., Aston, D.A., Cress, R.D., Ahn, D.K. & Kristiansen, J.J. Cutaneous melanoma in women. II. Phenotypic characteristics and other host-related factors. Am. J. Epidemiol. 141, 934-942 (1995).
2. Holly, E.A., Aston, D.A., Cress, R.D., Ahn, D.K. & Kristiansen, J.J. Cutaneous melanoma in women. I. Exposure to sunlight, ability to tan, and other risk factors related to ultraviolet light. Am. J. Epidemiol. 141, 923-933 (1995).
3. Naldi, L. et al. Cutaneous malignant melanoma in women. Phenotypic characteristics, sun exposure, and hormonal factors: a case-control study from Italy. Ann. Epidemiol. 15, 545-550 (2005).
4. Titus-Ernstoff, L. et al. Pigmentary characteristics and moles in relation to melanoma risk. Int. J. Cancer 116, 144-149 (2005).
5. Bataille, V. et al. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br. J. Cancer 73, 1605-1611 (1996).
6. Chang, Y.M. et al. A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int. J. Cancer 124, 420-428 (2009).
7. Cannon-Albright, L.A., Bishop, D.T., Goldgar, C. & Skolnick, M.H. Genetic predisposition to cancer. Important Adv. Oncol. 1991, 39-55 (1991).
8. Brown, K.M. et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat. Genet. 40, 838-840 (2008).
9. Bishop, D.T. et al. Genome-wide association study identifes three loci associated with melanoma risk. Nat. Genet. 41, 920-925 (2009).
10. Amos, C.I. et al. Genome-wide association study identifes novel loci predisposing to cutaneous melanoma. Hum. Mol. Genet. 20, 5012-5023 (2011).
11. Barrett, J.H. et al. Genome-wide association study identifes three new melanoma susceptibility loci. Nat. Genet. 43, 1108-1113 (2011).
12. Macgregor, S. et al. Genome-wide association study identifes a new melanoma susceptibility locus at 1q21.3. Nat. Genet. 43, 1114-1118 (2011).
13. Iles, M.M. et al. A variant in FTO shows association with melanoma risk not due to BMI. Nat. Genet. 45, 428-432 (2013).
14. Gudbjartsson, D.F. et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat. Genet. 40, 886-891 (2008).
15. Antonopoulou, K. et al. Updated feld synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma: the MelGene database. J. Invest. Dermatol. 135, 1074-1079 (2015).
16. Peña-Chilet, M. et al. Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population. BMC Cancer 13, 160 (2013).
17. Falchi, M. et al. Genome-wide association study identifes variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat. Genet. 41, 915-919 (2009).
18. Rafnar, T. et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41, 221-227 (2009).
19. Pooley, K.A. et al. No association between TERT-CLPTM1L single nucleotide polymorphism rs401681 and mean telomere length or cancer risk. Cancer Epidemiol. Biomarkers Prev. 19, 1862-1865 (2010).
20. Nan, H., Qureshi, A.A., Prescott, J., De Vivo, I. & Han, J. Genetic variants in telomere-maintaining genes and skin cancer risk. Hum. Genet. 129, 247-253 (2011).
21. Law, M.H. et al. Meta-analysis combining new and existing data sets confrms that the TERT-CLPTM1L locus infuences melanoma risk. J. Invest. Dermatol. 132, 485-487 (2012).
22. Mocellin, S. et al. Telomerase reverse transcriptase locus polymorphisms and cancer risk: a feld synopsis and meta-analysis. J. Natl. Cancer Inst. 104, 840-854 (2012).
23. Gomez, M. et al. PARP1 is a TRF2-associated poly(ADP-ribose)polymerase and protects eroded telomeres. Mol. Biol. Cell 17, 1686-1696 (2006).
24. Derheimer, F.A. & Kastan, M.B. Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett. 584, 3675-3681 (2010).
25. Bataille, V. et al. Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence in vivo. Cancer Epidemiol. Biomarkers Prev. 16, 1499-1502 (2007).
26. Han, J. et al. A prospective study of telomere length and the risk of skin cancer. J. Invest. Dermatol. 129, 415-421 (2009).
27. Burke, L.S. et al. Telomere length and the risk of cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. PLoS ONE 8, e71121 (2013).
28. Iles, M.M. et al. The effect on melanoma risk of genes previously associated with telomere length. J. Natl. Cancer Inst. 106, dju267 (2014).
29. Barrett, J.H. et al. Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions. Int. J. Cancer 136, 1351-1360 (2015).
30. de Bakker, P.I. et al. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum. Mol. Genet. 17, R122-R128 (2008).
31. Miyake, Y. et al. RPA-like mammalian Ctc1-Stn1-Ten1 complex binds to single-stranded DNA and protects telomeres independently of the Pot1 pathway. Mol. Cell 36, 193-206 (2009).
32. van Steensel, B. & de Lange, T. Control of telomere length by the human telomeric protein TRF1. Nature 385, 740-743 (1997).
33. Robles-Espinoza, C.D. et al. POT1 loss-of-function variants predispose to familial melanoma. Nat. Genet. 46, 478-481 (2014).
34. Shi, J. et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat. Genet. 46, 482-486 (2014).
35. Codd, V. et al. Identifcation of seven loci affecting mean telomere length and their association with disease. Nat. Genet. 45, 422-427 (2013).
36. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifes additional variants infuencing complex traits. Nat. Genet. 44, 369-375 (2012).
37. Ward, L.D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930-D934 (2012).
38. Bernstein, B.E. et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat. Biotechnol. 28, 1045-1048 (2010).
39. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
40. Boyle, A.P. et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22, 1790-1797 (2012).
41. Schadt, E.E. et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6, e107 (2008).
42. Innocenti, F. et al. Identifcation, replication, and functional fne-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet. 7, e1002078 (2011).
43. Grundberg, E. et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat. Genet. 44, 1084-1089 (2012).
44. Gajjar, K., Martin-Hirsch, P.L. & Martin, F.L. CYP1B1 and hormone-induced cancer. Cancer Lett. 324, 13-30 (2012).
45. Muthusamy, V. et al. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 66, 11187-11193 (2006).
46. Shen, M. et al. Quantitative assessment of the infuence of CYP1B1 polymorphisms and head and neck squamous cell carcinoma risk. Tumour Biol. 35, 3891-3897 (2014).
47. Stoilov, I., Akarsu, A.N. & Sarfarazi, M. Identifcation of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet. 6, 641-647 (1997).
48. 6-threonylcarbamoyladenosine in tRNA. J. Biol. Chem. 285, 28425-28433 (2010).
49. Brambillasca, S. et al. CDK5 regulatory subunit-associated protein 1-like 1 (CDKAL1) is a tail-anchored protein in the endoplasmic reticulum (ER) of insulinoma cells. J. Biol. Chem. 287, 41808-41819 (2012).
50. Praetorius, C. et al. A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell 155, 1022-1033 (2013).
51. Sulem, P. et al. Genetic determinants of hair, eye and skin pigmentation in Europeans. Nat. Genet. 39, 1443-1452 (2007).
52. Han, J. et al. A genome-wide association study identifes novel alleles associated with hair color and skin pigmentation. PLoS Genet. 4, e1000074 (2008).
53. Duffy, D.L. et al. IRF4 variants have age-specifc effects on nevus count and predispose to melanoma. Am. J. Hum. Genet. 87, 6-16 (2010).
54. Zhang, M. et al. Genome-wide association studies identify several new loci associated with pigmentation traits and skin cancer risk in European Americans. Hum. Mol. Genet. 22, 2948-2959 (2013).
55. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580-585 (2013).
56. GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648-660 (2015).
57. Persson, S. et al. Diversity of the protein disulfde isomerase family: identifcation of breast tumor induced Hag2 and Hag3 as novel members of the protein family. Mol. Phylogenet. Evol. 36, 734-740 (2005).
58. Fletcher, G.C. et al. hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br. J. Cancer 88, 579-585 (2003).
59. King, E.R. et al. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am. J. Surg. Pathol. 35, 904-912 (2011).
60. Kent, W.J. et al. The human genome browser at UCSC. Genome Res. 12, 996-1006 (2002).
61. Masutani, C. et al. Purifcation and cloning of a nucleotide excision repair complex involving the xeroderma pigmentosum group C protein and a human homologue of yeast RAD23. EMBO J. 13, 1831-1843 (1994).
62. Xia, Y. et al. TAL2, a helix-loop-helix gene activated by the (7;9)(q34;q32) translocation in human T-cell leukemia. Proc. Natl. Acad. Sci. USA 88, 11416-11420 (1991).
63. Wong, C.W. et al. Kruppel-like transcription factor 4 contributes to maintenance of telomerase activity in stem cells. Stem Cells 28, 1510-1517 (2010).
64. Hoffmeyer, K. et al. Wnt/β-catenin signaling regulates telomerase in stem cells and cancer cells. Science 336, 1549-1554 (2012).
65. Teerlink, C. et al. A unique genome-wide association analysis in extended Utah high-risk pedigrees identifes a novel melanoma risk variant on chromosome arm 10q. Hum. Genet. 131, 77-85 (2012).
66. Vízkeleti, L. et al. The role of CCND1 alterations during the progression of cutaneous malignant melanoma. Tumour Biol. 33, 2189-2199 (2012).
67. Young, R.J. et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res. 27, 590-600 (2014).
68. French, J.D. et al. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am. J. Hum. Genet. 92, 489-503 (2013).
69. Duffy, D.L. et al. A three-single-nucleotide polymorphism haplotype in intron 1 of OCA2 explains most human eye-color variation. Am. J. Hum. Genet. 80, 241-252 (2007).
70. Ruiz, Y. et al. Further development of forensic eye color predictive tests. Forensic Sci. Int. Genet. 7, 28-40 (2013).
71. Li, M.X., Yeung, J.M., Cherny, S.S. & Sham, P.C. Evaluating the effective numbers of independent tests and signifcant p-value thresholds in commercial genotyping arrays and public imputation reference datasets. Hum. Genet. 131, 747-756 (2012).
72. Price, A.L. et al. Principal components analysis corrects for stratifcation in genome-wide association studies. Nat. Genet. 38, 904-909 (2006).
73. Howie, B.N., Donnelly, P. & Marchini, J. A fexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
74. Marchini, J. & Howie, B. Genotype imputation for genome-wide association studies. Nat. Rev. Genet. 11, 499-511 (2010).
75. Li, Y., Willer, C.J., Ding, J., Scheet, P. & Abecasis, G.R. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet. Epidemiol. 34, 816-834 (2010).
76. Li, Y., Willer, C., Sanna, S. & Abecasis, G. Genotype imputation. Annu. Rev. Genomics Hum. Genet. 10, 387-406 (2009).
77. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G.R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat. Genet. 44, 955-959 (2012).
78. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467, 1061-1073 (2010).
79. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906-913 (2007).
80. Higgins, J.P. & Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539-1558 (2002).
81. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 7, 177-188 (1986).
82. Mägi, R. & Morris, A.P. GWAMA: software for genome-wide association meta-analysis. BMC Bioinformatics 11, 288 (2010).
83. Gabriel, S., Ziaugra, L. & Tabbaa, D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr. Protoc. Hum. Genet. Chapter 2, Unit 2.12 (2009).
84. Cho, E., Rosner, B.A., Feskanich, D. & Colditz, G.A. Risk factors and individual probabilities of melanoma for whites. J. Clin. Oncol. 23, 2669-2675 (2005).
85. Newton-Bishop, J.A. et al. Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom. Cancer Epidemiol. Biomarkers Prev. 19, 2043-2054 (2010).
86. Newton-Bishop, J.A. et al. Relationship between sun exposure and melanoma risk for tumours in different body sites in a large case-control study in a temperate climate. Eur. J. Cancer 47, 732-741 (2011).
87. 3 levels are associated with Breslow thickness at presentation and survival from melanoma. J. Clin. Oncol. 27, 5439-5444 (2009).
88. Edwards, S.L., Beesley, J., French, J.D. & Dunning, A.M. Beyond GWASs: illuminating the dark road from association to function. Am. J. Hum. Genet. 93, 779-797 (2013).
89. Nica, A.C. et al. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet. 7, e1002003 (2011).
90. Pruim, R.J. et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26, 2336-2337 (2010).
91. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007).
92. Danecek, P. et al. The variant call format and VCFtools. Bioinformatics 27, 2156-2158 (2011).